Vaccine immunotherapy for immune suppressed patients

Abstract

A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.

1 . A method for unblocking immunization at a regional lymph node by: 
 promoting differentiation and maturation of immature dendritic cells in a regional lymphnode and;    allowing presentation by resulting mature dendritic cells of antigen to T-cells to gain immunization of the T-cells to the antigen.    
     
     
         2 . The method according to  claim 1 , wherein said promoting step is further defined as administering a natural cytokine mixture (NCM) perilymphatically into lymphatics that drain into lymph nodes regional to a lesion to be treated.  
     
     
         3 . The method according to  claim 2 , wherein the lesion is cancerous or another persistent lesion.  
     
     
         4 . The method according to  claim 3 , wherein the presented lesion is infectious.  
     
     
         5 . The method according to  claim 1 , wherein the antigen is an endogenous antigen.  
     
     
         6 . The method according to  claim 1 , wherein the antigen is an exogenous antigen.  
     
     
         7 . The method according to  claim 2  wherein said administering step is further defined as injecting the NCM perilymphatically, intralymphatically, intranodally, intrasplenically, subcuntaneously, intramuscularly or intracutaneously.  
     
     
         8 . A method of inducing immunization to cancer or persistent lesions by administering an effective amount of an exogenous antigen and an adjuvant consisting of a natural cytokine mixture (NCM).  
     
     
         9 . A method according to  claim 7 , wherein said administering step is further defined as administering an NCM including IL-1, IL-2, IL-6, IL-8, δIFN and TNFα.  
     
     
         10 . A method according to  claim 8  wherein said administering step is further defined as injecting the NCM perilymphatically, intralymphatically, intranodally, intrasplenically, subcutaneously, intramuscularly or intracutaneously.  
     
     
         11 . A method for unblocking immunization by overcoming mild to moderate T cell depletion and restoring T cell immune response by inducing production of naïve T cells.  
     
     
         12 . A method according to  claim 11 , wherein said inducing step is further defined as administering a natural cytokine mixture (NCM).  
     
     
         13 . A method according to  claim 11  wherein said administering step is further defined as injecting the NCM perilymphatically, intralymphatically, intranodally, intrasplenically, subcutaneously, intramuscularly or intracutaneously.  
     
     
         14 . A method according to  claim 12 , wherein said administering step is further defined as injecting an NCM including IL-1, IL-2, IL-6, IL-8, δIFN and TNFα.  
     
     
         15 . A method according to  claim 14 , wherein said administering step includes administering about 150-600 units of IL-2 per injection in the NCM.  
     
     
         16 . A method according to  claim 11 , wherein said blocking and inducing steps are further defined as codelivering cyclophosphamide and a nonsteroidal anti-inflammatory drug (NSAID).  
     
     
         17 . A method of treating a cancer or other persistent lesion in an immune suppressed patient by administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenously administering antigen from the cancer or persistent lesion.  
     
     
         18 . A method according to  claim 14 , wherein said administering step is further defined as injecting an NCM including IL-1, IL-2, IL-6, IL-8, TNFα and δIFN.  
     
     
         19 . A method according to  claim 18 , wherein said administering step is further defined as injecting an NCM including IL-1, IL-2, IL-6, IL-8, TNFα and δIFN.  
     
     
         20 . A method according to  claim 17 , further including the steps of blocking endogenous suppression of T-cells directly or indirectly by the endogenous lesion being treated.  
     
     
         21 . A method according to  claim 17 , wherein said blocking and inducing steps are further defined as codelivering cyclophosphamide and a nonsteroidal anti-inflammatory drug (NSAID).  
     
     
         22 . A method according to  claim 21 , wherein the NSAIDS is selected from the group including indomethacin, ibuprofen, vioxx®-(rofecoxib), CELEBREX® (celecoxib) and other related compounds.  
     
     
         23 . A method of vaccine immunotherapy including the steps of: 
 inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens.    
     
     
         24 . A method according to  claim 23 , wherein said exposing step is further defined as exposing the naïve T-cells to endogenously processed peptide preparation resident in regional nodes of a patient who possesses a lesion.  
     
     
         25 . A method according to  claim 24 , wherein the lesion is cancerous or infectious.  
     
     
         26 . A method according to  claim 23 , wherein said exposing step is further defined as administering an exogenously produced antigen.  
     
     
         27 . A method according to  claim 23 , wherein said antigen is otherwise non-immunogenic peptide.  
     
     
         28 . A method according to  claim 23 , wherein said exposing step is further defined as immunizing he naïve T-cells with matured peptide presenting dendritic cells at a lymph node distal from a lesion to be treated.  
     
     
         29 . A method of treating lymphocytopoenic by administering an effective amount of a natural cytokine mixture.  
     
     
         30 . The method according to  claim 1  further including the step of stimulating naïve T-cell production.  
     
     
         31 . The method according to  claim 1  further including the step of actuating dendritic cells to promote antigen presentation.